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ABSTRACT
Aims To examine cross-national patterns of 12-month substance use disorder (SUD) treatment andminimally adequate
treatment (MAT), and associations with mental disorder comorbidity. Design Cross-sectional, representative household
surveys. Setting Twenty-seven surveys from 25 countries of the WHO World Mental Health Survey Initiative.
Participants A total of 2446 people with past-year DSM-IV SUD diagnoses (alcohol or illicit drug abuse and depen-
dence). Measurements Outcomes were SUD treatment, defined as having either received professional treatment or
attended a self-help group for substance-related problems in the past 12 months, and MAT, defined as having either four
or more SUD treatment visits to a health-care professional, six or more visits to a non-health-care professional or being in
ongoing treatment at the time of interview. Covariates weremental disorder comorbidity and several socio-economic char-
acteristics. Pooled estimates reflect country sample sizes rather than population sizes. Findings Of respondents with past-
year SUD, 11.0% [standard error (SE) = 0.8] received past 12-month SUD treatment. SUD treatment was more common
among people with comorbidmental disorders than with pure SUDs (18.1%, SE = 1.6 versus 6.8%, SE = 0.7), as wasMAT
(84.0%, SE = 2.5 versus 68.3%, SE = 3.8) and treatment by health-care professionals (88.9%, SE = 1.9 versus 78.8%,
SE = 3.0) among treated SUD cases. Adjusting for socio-economic characteristics, mental disorder comorbidity doubled
the odds of SUD treatment [odds ratio (OR) = 2.34; 95% confidence interval (CI) = 1.71–3.20], MAT among SUD cases
(OR = 2.75; 95% CI = 1.90–3.97) andMATamong treated cases (OR = 2.48; 95% CI = 1.23–5.02). Patternswere similar
within country income groups, although the proportions receiving SUD treatment and MAT were higher in high-
than low-/middle-income countries. Conclusions Few people with past-year substance use disorders receive adequate
12-month substance use disorder treatment, even when comorbid with a mental disorder. This is largely due to the low
proportion of people receiving any substance use disorder treatment, as the proportion of patients whose treatment is at
least minimally adequate is high.
Keywords Comorbidity, mental disorders, minimally adequate treatment, substance use disorders, treatment, World
Mental Health Surveys.
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INTRODUCTION
Substance use disorders (SUDs), including alcohol and il-
licit drug abuse and dependence, are conservatively
estimated to affect 2.6% of the world’s population each
year [1]. SUDs were the eighth leading cause of risk-
attributable disability-adjusted life-years globally in 2016
and the fourth to fifth leading cause in socio-economically
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developed regions [2]. Despite the availability of effective in-
terventions for SUD, few people with these disorders receive
treatment and even fewer receive minimally adequate
treatment (MAT); that is, an amount that could reasonably
be expected to provide the opportunity to begin potentially
effective intervention [1,3–6].
Among people with past-year SUDs, having a comorbid
mental disorder increases the likelihood of receiving treat-
ment [7–10]. Estimates suggest that more than 40% of
people with past-year SUDs have a comorbid mental disor-
der, most commonly a mood or anxiety disorder [11,12].
SUD cases with comorbid mental disorders have a more se-
vere and disabling course of illness, poorer social and clin-
ical outcomes if under-treated, and more complications
with treatment than those with pure SUDs [13]. Treat-
ment guidelines recommend that when SUDs and mental
disorders co-occur, each disorder should be treated in its
own right [14]. Countries vary in their funding and organi-
zation of SUD services. High-income countries are more
likely to have dedicated funding for specialized SUD services
and to administer these separately frommental health ser-
vices [13]. For these reasons, an understanding is needed
of the extent to which people with past-year SUDs received
‘SUD treatment’ (i.e. for the purpose of treating an SUD),
and how this differs according to comorbidity status and
across countries.
Most population estimates of SUD treatment have come
from the United States, showing that only 8–15% of people
with past-year SUDs received SUD treatment in the preced-
ing 12 months [7,8]. SUD treatment tended to be more
common for SUD cases with comorbid mental disorders
(10.5–42.0% [15–17]) than those with pure SUDs (6.7–
10% [17,18]). People with past-year SUDs also had 1.3–
3.4 times greater probability of receiving mental health
treatment than SUD treatment, even if they did not have
a comorbid mental disorder [7,15–18]. This may occur
for several reasons. For example, people with pure SUDs
may have sought mental health treatment because they
perceived their substance use problem as a mental health
problem; people with SUDs and comorbid mental disorders
may perceive the latter as the most troubling. People with
SUDs, regardless of comorbidity, may regard mental health
services as more adequate, acceptable or available
[5,7,17,18]. Co-occurring SUDs and mental disorders in-
fluence each other [13]; however, the extent to which
treatment for a comorbid mental disorder will also be effec-
tive in alleviating the SUD is not known, and would proba-
bly vary greatly depending on the aetiology, severity and
type of the comorbid disorder.
Reducing the burden of SUDs requires improvements in
the coverage and quality of SUD treatment. In clinical sam-
ples, high-quality SUD treatment (as indicated by process-
based measures of treatment intensity, therapeutic content
and continuity) has been associated with better outcomes
for people with SUDs [19–21]. In an analysis of population
data from 26 countries in the World Health Organization’s
(WHO) World Mental Health Survey (WMHS) initiative
[1], information about type and number of health-care
visits was used to estimate MAT among people with past-
year SUDs who had received treatment for emotional or
substance use problems in the previous 12 months. Only
7.1% of people with past-year SUDs received MAT, ranging
from 1.0% in low–/lower–middle-income countries to
10.3% in high-income countries [1]. However, correspond-
ing estimates among those who received SUD treatment
specifically, and associations with mental disorder comor-
bidity, are lacking.
We examined cross-national patterns of 12-month
SUD treatment among people with pure and comorbid
past-year SUDs. Specific aims were to: (1) estimate the
proportions receiving SUD treatment and MAT by comor-
bidity status and country income level; (2) examine the
sectors in which people received SUD treatment and
MAT, namely from health-care professionals and non-
health-care professionals; and (3) examine potential asso-
ciations of mental disorder comorbidity with SUD treat-
ment and MAT.
METHODS
Sample
Data came from 27 surveys in 25 countries participating
in the WMHS (Table 1). Five were classified as low- and
lower–middle-income (Colombia, Iraq, Nigeria, China
and Peru), six as upper–middle-income (Brazil, Bulgaria,
Colombia, Lebanon, Mexico and Romania) and 16 as
high-income (Argentina, Australia, Belgium, France,
Germany, Israel, Italy, Japan, the Netherlands, New
Zealand, Northern Ireland, Poland, Portugal, Spain,
Spain–Murcia, and the United States). Each survey’s
interviewing sample size was determined by its available
resources and data collection budget; however, all utilized
a probability sample design for the selection of a represen-
tative sample of their target population, with the majority
using multi-stage, clustered area probability designs. The
weighted average response rate throughout all countries
was 68.5% (Table 1).
SUDs were assessed with the WHO Composite Inter-
national Diagnostic Interview (CIDI) version 3.0, a vali-
dated fully structured interview designed to generate
life-time and 12-month diagnoses of mental disorders ac-
cording to DSM-IV and ICD-10 criteria. The interview
was developed in English and standardized protocols
were used to adapt the CIDI for use in each participating
country [22,23].
All respondents completed Part I of the CIDI, which
contained a diagnostic assessment of core mental disor-
ders. Respondents identifiedwith a disorder during the Part
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I assessment and a probability sample of other Part I re-
spondents were administered Part II, which assessed disor-
ders of secondary interest and correlates. Analyses in the
current study are restricted to respondents with a past-year
SUD (DSM-IV diagnoses of alcohol or illicit drug abuse or
dependence).
Table 1 Survey characteristics.
Countrya Sample characteristics
Field
dates
Age
range
Sample size
Response
ratebPart 1 Part 2
Low- and lower–middle-income countries
Colombia All urban areas of the country
(about 73% of the total national
population)
2003 18–65 4426 2381 87.7%
Iraq Nationally representative 2006–7 18–96 4332 4332 95.2%
Nigeria 21 of the 36 states in the country
(approximately 57% of the national
population)
2002–4 18–100 6752 2143 79.3%
China Beijing and Shanghai metropolitan
areas
2001–3 18–70 5201 1628 74.7%
Peru 5 urban areas of the country
(approximately 38% of the total
national population).
2004–5 18–65 3930 1801 90.2%
Total 24641 12285 83.7%
Upper-middle-income countries
Brazil São Paulo metropolitan area 2005–8 18–93 5037 2942 81.3%
Bulgaria Nationally representative 2002–6 18–98 5318 2233 72.0%
Colombia (Medellin) Medellin metropolitan area 2011–12 19–65 3261 1673 97.2%
Lebanon Nationally representative 2002–3 18–94 2857 1031 70.0%
Mexico All urban areas of the country
(approximately 75% of the total
national population)
2001–2 18–65 5782 2362 76.6%
Romania Nationally representative 2005–6 18–96 2357 2357 70.9%
Total 24612 12598 77.2%
High-income countries
Argentina 8 largest urban areas of the
country: approximately 50% of
the total national population.
2015 18–98 3927 2116 77.3%
Australia Nationally representative 2007 18–85 8463 8463 60.0%
Belgium Nationally representative 2001–2 18–95 2419 1043 50.6%
France Nationally representative 2001–2 18–97 2894 1436 45.9%
Germany Nationally representative 2002–3 19–95 3555 1323 57.8%
Israel Nationally representative 2003–4 21–98 4859 4859 72.6%
Italy Nationally representative 2001–2 18–100 4712 1779 71.3%
Japan 11 metropolitan areas 2002–6 20–98 4129 1682 55.1%
The Netherlands Nationally representative 2002–3 18–95 2372 1094 56.4%
New Zealand Nationally representative 2004–5 18–98 12790 7312 73.3%
Northern Ireland Nationally representative 2005–8 18–97 4340 1986 68.4%
Poland Nationally representative 2010–11 18–65 10081 4000 50.4%
Portugal Nationally representative 2008–9 18–81 3849 2060 57.3%
Spain Nationally representative 2001–2 18–98 5473 2121 78.6%
Spain-Murcia Murcia region 2010–12 18–96 2621 1459 67.4%
United States Nationally representative 2001–3 18–99 9282 5692 70.9%
Total 85766 48425 63.1%
Overall sample 135 019 73308 68.5%
Bold type indicates country income groupings and corresponding summary values. aThe World Bank (2012) Data. Accessed 12 May 2012 at: http://data.
world bank.org/country. Some of theWMH countries havemoved into new income categories since the surveyswere conducted. The income groupings above
reflect the status of each country at the time of data collection. bThe response rate is calculated as the ratio of the number of households in which an interview
was completed to the number of households originally sampled, excluding from the denominator households known not to be eligible either because of being
vacant at the time of initial contact or because the residents were unable to speak the designated languages of the survey.
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All surveys were administered face-to-face by trained
lay interviewers. Interviewer training and quality control
procedures were standardized across surveys [24]. In-
formed consent was obtained according to protocols en-
dorsed by local institutional review boards.
Definitions of SUD treatment andminimally adequate SUD
treatment
Among participants with an SUD, SUD treatment was de-
fined as having either received treatment from a health-
care professional or attended a self-help group for
substance-related problems at any time in the past year.
Treatment was classified as having come from a health-
care professional if a speciality mental health professional
(psychiatrist, psychologist, other mental health profes-
sional in any setting, social worker or counsellor in a men-
tal health speciality treatment setting or a mental health
hotline) or general professional (primary care doctor, other
medical doctor or other health-care professional in a med-
ical setting) had been consulted. If only non-medical pro-
fessionals (social worker or counsellor in a non-medical
setting, religious or spiritual adviser or healer) or self-help
groups had been consulted, treatment was classified as
non-health care.
Among people who received any SUD treatment, mini-
mally adequate treatment (MAT) was defined as having ei-
ther at least four treatment visits to a health-care
professional, at least six visits to a non-health-care profes-
sional or self-help group or being in continuing treatment
at the time of interview. These thresholds represent the
minimum number of visits reasonably expected to provide
opportunity to instigate the necessary steps at the begin-
ning of any SUD or mental disorder intervention, including
patient’s report of symptoms, diagnosis, formulation of
treatment plan, presentation of diagnosis and plan to the
patient, patient acceptance of the plan, for intervention to
be started and for the patient to experience and make at
least some commitment to the intervention [6].
Comorbid mental disorders
To investigate the association of a comorbid mental disor-
der with receipt of SUD treatment, participants with a
past-year diagnosis of major depressive disorder, general-
ized anxiety disorder, bipolar disorders, panic disorder, so-
cial disorder, specific disorder and agoraphobia were
identified. Standardized diagnostic hierarchy rules among
these disorders were applied, where appropriate.
Statistical methods
All analyses were based on weighted data to make
samples representative of the target population’s socio-
demographic characteristics. Individual-level weights were
used to adjust for differences in probability of selection, and
to match the socio-demographics of the sample to those of
the population. To adjust for differential sampling into Part
II, Part II respondents were weighted by the inverse of their
probability of selection into Part II, equalizing prevalence
estimates in the weighted Part II and Part I samples. Stan-
dard errors were estimated using Taylor Series linearization
taking into account weighting, clustering and stratifica-
tion. Prevalence estimates were produced in PROC
SURVEYFREQ, and logistic regression analyses in PROC
SURVEYLOGISTIC, both implemented in SAS version 9.0.
Surveys are combined for purposes of pooled estimates
based on sample sizes, rather than sizes of the populations
of the countries surveyed. Pooled prevalence estimates
therefore represent the weighted mean across our surveys,
where weights are based on survey sample size. Further-
more, all regression models included dummy control vari-
ables for survey so that coefficients for other predictors
could be interpreted as pooled within-survey coefficients.
This approach, which implicitly assumed that within-
survey slopes were constant across surveys, was imple-
mented because the degree of survey-level variability at-
tributable to the parameter of main interest was found to
be modest, and allowing (in a random-slope model) for
inter-country variation in that slope had little effect on
the mean slope estimate and its standard error.
To test for differences between SUD only and SUD and
at least one comorbid mental disorder, and high- and
low–middle-income countries, in relation to the key vari-
ables of interest related to the aims of the paper, χ2 tests
were applied. Logistic regression analyses were conducted
to predict 12-month SUD treatment and MAT among all
people with a past-year SUD, and MAT among the subset
of past-year SUD cases with any 12-month SUD treatment.
To investigate the associations of comorbid mental disor-
ders with SUD treatment, we defined a single indicator var-
iable capturing the presence of any past-year depression,
bipolar, panic, generalized anxiety, social, specific or agora-
phobia disorder. Due to low counts within select disorders,
modelling of individual mental disorder indicators was not
feasible.
Other covariates included sex, age at interview
(< 25, 25–34, 35–44 and 45+), personal income defined
in within-country quartiles (low, low–average, high–
average and high), marriage status (never married,
married/cohabitating, separated/widowed/divorced), edu-
cation level defined within-country (low, low–average,
high–average and high) [25] and country income level
[high- and low-/low–middle/upper–middle (or ‘low–middle’
levels combined due to low statistical power) from Table 1]
of the survey country or region. We conducted analyses
with all countries pooled, and subgroup analyses bycountry
income level; however, there was not enough statistical
power to make separate estimates for each country.
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We conducted sensitivity analyses among a subset of
surveys that captured information regarding physical
health comorbidities in a consistent manner (1986 re-
spondents with past-year SUD). The physical comorbidi-
ties included past-year presence of any back or neck
problems, headaches, chronic pain, allergies, diabetes, ul-
cer(s), HIV infection, epilepsy or seizures, and cancer. We
also included life-time presence of heart disease, hyper-
tension, asthma and chronic lung disease, as these condi-
tions are typically chronic and require ongoing
management or treatment. We modelled the number of
past-year physical comorbidities as: exactly one, exactly
two and three or more.
Parameter coefficients and standard errors are reported
as odds ratios (OR) and 95% confidence intervals (CIs) with
statistical significance evaluated using 0.05-level two-sided
tests.
RESULTS
Among all countries, 2446 (2.6%) people in the WMHS
met criteria for a past-year SUD, with prevalence higher
in high- (3.0%) than in low–middle-income countries
(1.9%). Overall, approximately one in three people with a
past-year SUD also had at least one other mental disorder
in the same time-frame, with higher comorbidity among
those in high- than in low–middle-income countries
(Table 2).
SUD treatment
One in nine past-year SUD cases received SUD treatment in
the past 12 months. Among past-year SUD cases, SUD
treatment was twice as common in high- compared to
low–middle-income countries, and among those with a co-
morbidmental disorder compared to those with a diagnosis
of SUD only. This pattern was consistent in high- and low–
middle-income countries.
Minimally adequate treatment (MAT)
Among those who received SUD treatment, more than
three-quarters met MAT thresholds (Table 2). MAT was
more common in high- than in low–middle-income coun-
tries, and among people with a comorbid disorder com-
pared to those with a SUD only.
SUD treatment professionals
Most people with 12-month SUD treatment were treated
by at least one health-care professional. The use of
health-care professionals for treatment was more common
among people with a comorbid disorder than among those
with an SUD only across all countries and in high-income
surveys. Among people who received SUD treatment from
a health-care professional, most received MAT. MAT was
more common in high-income countries than low–mid-
dle-income countries, and was more common among
those with a comorbid disorder than among those with
an SUD only in low–middle-income countries, but not in
high-income countries.
The use of non-health-care professionals as the sole
source of SUD treatment was uncommon. Levels of MAT
from a non-health-care professional were higher among
people with a comorbid disorder compared to those with
a SUD only in both the pooled and high-income surveys.
Although there was no difference between country in-
come groups in the proportion of SUD cases obtaining
treatment from a health-care professional, MAT provision
was more common for those treated by health-care profes-
sionals in high- than low–middle-income countries.
Supporting information, Table S1 presents bivariate co-
morbid mental disorder odds ratios for all outcomes shown
in Table 2.
Comorbid mental disorder and SUD treatment
Results from logistic regression analyses investigating the
association of comorbid disorder with receipt of any SUD
treatment and MAT are presented in Table 3 and Fig. 1.
Adjusting for all socio-demographics, the presence of a co-
morbid disorder more than doubled the odds of receiving
SUD treatment, MAT among SUD cases and MAT among
treated cases. Consistent results were observed within
country-level income groups.
In sensitivity analyses, after adjusting for number of
past-year physical comorbidities, people with past-year co-
morbid mental disorder still had higher odds of SUD treat-
ment (OR = 1.75; 95 CI = 1.27–2.40) and MAT
(OR = 2.13; 95% CI = 1.47–3.09) (details available upon
request).
Additional models investigated potential differences in
correlates of SUD treatment by type of professional. These,
along with the full model results from analyses shown in
Table 3, are shown in Supporting information, Tables S2–
S10. These show that the patterns observed in the main
analyses were all similar for those receiving SUD treatment
from a health-care professional specifically and, despite
small numbers, were generally similar for those receiving
non-health-care treatment only.
DISCUSSION
We are aware of no previous comparative cross-national
data on SUD treatment. We found SUD treatment among
past-year SUD cases to be low across all countries studied
(11.0%). Most treated cases received MAT but, because of
the low coverage, only 8.5% of all SUD cases received ade-
quate SUD treatment. MAT was more common among
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SUD cases with comorbid mental disorders, compared to
cases with pure SUDs, due to the higher proportions receiv-
ing any SUD treatment and receiving MATonce treatment
had started. These patterns were similar within country
income groups, even though SUD treatment and MAT
were twice as common among SUD cases from high-
income countries compared to low–middle-income
countries.
Table 3 Logistic regression results investigating association between having a comorbid mental disorder and receiving ‘any‘ and
‘minimally adequate‘ 12-month substance use disorder treatment.
Response Among those with …
Comorbid mental disordera (Ref: no)
Bivariate Multivariableb
OR (95% CI) OR (95% CI)
All countries
Any 12-month SUD treatmentc Past-year SUDd 2.72* (2.01–3.67) 2.34* (1.71–3.20)
Minimally adequate treatmentd Any 12-month SUD treatment 2.92* (1.54–5.53) 2.48* (1.23–5.02)
Minimally adequate treatmentd Past-year SUDd 3.34* (2.35–4.74) 2.75* (1.90–3.97)
Low–middle-income countries
Any 12-month SUD treatmentc Past-year SUDd 2.40* (1.36–4.21) 2.44* (1.38–4.32)
Minimally adequate treatmentd Any 12-month SUD treatment -e -e
Minimally adequate treatmentd Past-year SUDd 2.82* (1.48–5.39) 2.97* (1.55–5.69)
High-income countries
Any 12-month SUD treatmentc Past-year SUDd 2.71* (1.91–3.84) 2.29* (1.60–3.29)
Minimally adequate treatmentd Any 12-month SUD treatment 3.14* (1.48–6.67) 2.49* (1.09–5.68)
Minimally adequate treatmentd Past-year SUDd 3.29* (2.21–4.91) 2.68* (1.75–4.10)
SUD = substance use disorder; OR = odds ratio; CI = confidence interval *Significant at the 5% significance level. All logistic regression analyses are based on
weighted Part II data and include survey dummy variables. aIncludes: depression (with hierarchy); generalized anxiety disorder (with hierarchy), (broad) bi-
polar disorder (bipolar I, bipolar II and bipolar subthreshold), panic disorder, social phobia, specific phobia and agoraphobia (without panic) disorder.
bMultivariable models adjust for age (< 25 years, 25–34 years, 35–44 years and 45+ years), gender, income level (survey-specific levels defined as low,
low-average, high-average and high), marriage status (never married, married/cohabitating and separated/widowed/divorced) and education level (sur-
vey-specific levels defined as low, low–average, high–average and high). In the models including all countries, country income level (low–middle and high)
was also included. cAny SUD treatment was defined as having either received professional treatment or attended a self-help group for substance-related prob-
lems in the past year. dMinimally adequate treatment is defined as having received SUD-specific professional treatment in the past 12 months and (having
received four or more medical doctor visits or six or more visits to a non-medical doctor or still in treatment at the time of interview). eAnalyses excluded
as the denominator contained fewer than 50 cases.
Figure 1 Forest plot with 95% confidence intervals for odds ratios of comorbid mental disorder (reference = no) associated with receipt of any
treatment among all substance use disorders (SUDs), minimally adequate treatment (MAT) among treated SUDs and MAT among all SUDs, for
all countries combined (square), and by low–middle-income (circle) and high-income (diamond) countries (reference line at 1); note: there were
not enough cases to analyse MAT among treated SUDs in low-/middle-income countries only, so no estimate is provided. [Colour figure can be
viewed at wileyonlinelibrary.com]
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Limitations
There were important limitations. First, our MAT criteria
would ideally have included receipt of potentially beneficial
pharmacological treatments for SUDs (e.g. naltrexone for
alcohol dependence [26] and opioid substitution therapy
for opioid dependence [25]). However, medication use
(types, timing, duration and adherence) was not covered
in sufficient detail in theWMHS. The criteria counted visits
to health-care professionals who are able to prescribe and
monitor medications.
Second, due to low counts, the individual impact of spe-
cific combinations of SUDs and mental disorders on receipt
of SUD treatment could not be investigated. The coefficient
representing the impact of any comorbid mental disorder
represents themean effect of any and all disorders. Patterns
of treatment may vary according to different combinations
of diagnoses [27] or other latent structures [6,28]. This is
an avenue for future work.
Third, we assumed that respondents could reliably
identify that they had received treatment for substance-
related problems. Studies have found acceptable levels of
agreement between self-reported use of substance use ser-
vices and administrative records or other independent
sources among people with substance use problems or dis-
orders [29–33], with better agreement for aggregate mea-
sures than for detailed measures [32,33] and poorer
agreement among high-volume service users [29,30].
Fourth, to our knowledge, the predictive validity of the
MAT criteria used in this study has not been established.
Fifth, the comparatively lower disability associated with
substance abuse compared to dependence may, in part, ex-
plain the low treatment proportions; however, there was
not enough statistical power to conduct separate analyses
for abuse and dependence.
Sixth, there may be between-country variations in will-
ingness to report use of various substances, due to legal
frameworks, cultural norms and other factors.
Seventh, the number of reported visits used in evaluat-
ing MAT may potentially include visits made for mental
health problems other than SUDs, so the proportion receiv-
ing MAT may be even lower than reported here.
Finally, our sensitivity analyses included many, but not
all, physical conditions (e.g. stroke, liver problems) that are
prevalent among people with SUDs or may affect SUD
treatment [34,35]. General limitations of the WMHS are
discussed in detail elsewhere [1,36].
Implications
Few past-year SUD cases received 12-month SUD treat-
ment. Our estimates of 12-month SUD treatment in high-
income countries were broadly similar to independent US
estimates for people with any SUD (12.5 versus 8–15%
[7,8]), comorbid SUD and mental disorder (19.9 ver-
sus 10.5–42.0% [15–17]) and SUD only (4.8 versus
6.7%–10% [17,18]). Equivalent comparisons for low–
middle-income countries were not possible. Reasons for
low SUD treatment proportions are many and varied
[37–44]. Systemic factors (e.g. low policy priority, scarcity
of services and appropriately trained professionals, lack of
community-based care options, out-of-pocket payment
models) and community factors (e.g. stigmatizing commu-
nity attitudes) are especially relevant in low–middle-
income countries [45–47].
Only 8.5% of past-year SUD cases received MAT, lower
than has been reported for depression [36] but similar to
anxiety disorders [48] (noting that the MAT criteria in
those studies [36,48] took account of medication use
which the current study could not). This was due largely
to the low proportion receiving any SUD treatment, as
the proportion of treated SUD cases who received MAT
was high. A US study showed that people with SUDs had
more treatment visits (median 6.6) than people with men-
tal disorders (2.4–6.0, depending on disorder) [4]. To-
gether, these findings could suggest that people with
SUDs who commence treatment are committed to
obtaining a positive outcome and therefore persist with it.
In the pooled professional samples, lower proportions of
SUD treatment and MAT among pure SUD cases could in-
dicate that this group are at greater risk of under-
treatment. However, SUD cases with comorbid mental dis-
orders have worse clinical presentation and outcomes [13],
and are more likely to report unmet treatment needs
[42,49]. Moreover, longitudinal studies show that people
with SUDs who do not access treatment have, on average,
less severe disorders and more favourable outcomes than
treatment users, suggesting that many people appropri-
ately self-select for treatment [50,51]. Further examina-
tion of the relationship between clinical characteristics of
SUDs (e.g. comorbidity, severity, persistence and disability)
and recent and life-time treatment patterns may help to
identify those who should be the focus of policy and service
responses to reduce the treatment gap for SUDs.
SUD treatment and MAT proportions in high-income
countries were double those in low–middle-income coun-
tries, consistent with other evidence of SUD intervention
coverage [52]. Moreover, in low–middle-income countries,
the proportion receiving MAT was lower for those with
pure, compared to comorbid, SUDs. The WHO Mental
Health Gap Action Programme (mhGAP) Intervention
Guide [53,54] has identified evidence-based interventions
for SUDs that could feasibly be scaled-up in high- and
low–middle-income countries. These include: self-
monitoring of high-risk behaviours for substance abuse;
guideline-concordant pharmacological and psychological
management of alcohol use disorders; and methadone
maintenance therapy for opioid dependence and
1454 Meredith G. Harris et al.
© 2019 Society for the Study of Addiction Addiction, 114, 1446–1459
buprenorphine as opioid substitution therapy [55]. In low–
middle-income countries specifically, there is good evidence
that contextually appropriate regulatory and legal controls
can reduce alcohol use and associated harms [56]. Preven-
tive and treatment interventions—e.g. integrating
awareness-raising of alcohol and drug misuse into the
work-place and collaborative community-based care—are
supported by good evidence from high-income countries
but require more robust evidence from low–middle-income
settings [55,56]. Scaling-up will require significant invest-
ment to increase system capacity, especially in countries
with under-developed SUD treatment services and without
substance use policies [39,47]. Improvingwork-force avail-
ability and training are critical to improving detection and
quality of care of SUDs [38]; in contexts where specialist
skills are scarce, task sharing and transitioning clinical spe-
cialists from direct service provision to supervisory roles
may help to build capacity [55].
CONCLUSIONS
Improving treatment coverage and adequacy for SUDs is a
global health priority [57]. We found that few people with
past-year SUDs received MAT, even when comorbid with a
mental disorder. Scaling-up of evidence-based interven-
tions, informed bymore robust evidence of population need
and intervention efficacy in low–middle-income settings,
could help address these treatment gaps.
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Table S2 Logistic regression results investigating variables
associated with receiving ‘any‘ and ‘minimally adequate‘
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that received only non-healthcare treatment (N = 2402).
Table S5 Logistic regression results investigating variables
associated with receiving ‘any‘ and ‘minimally adequate‘
treatment from a non-healthcare professional; excluding
those that received any healthcare treatment (N = 2190).
Table S6Multivariable logistic regression results investigat-
ing variables associated with receiving ‘any‘ and ‘mini-
mally adequate‘ 12-month substance use disorder
treatment; separated into Low/Middle and High income
countries.
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ing variables associated with receiving healthcare treat-
ment among those with any 12-month substance
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income countries.
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mally adequate‘ 12 month substance use disorder
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that received only non-healthcare treatment.
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